Outcomes of mini-invasive ultrasound-guided percutaneous interventions in non-parasitic hepatic cysts and polycystic liver disease

Aim. To evaluate short- and long-term outcomes of percutaneous sclerotherapy in patients with non-parasitic hepatic cysts and polycystic liver disease. Materials and methods. Between 2016 and 2023, 106 patients with non-parasitic hepatic cysts underwent interventions. Multiple cysts were observed in 38 patients (35%) and polycystic liver disease was diagnosed in 24 patients (23%). Results. Complications were observed in 10 patients (9%). In six of them, cyst cavity infection occurred, which required repeat drainage (Clavien–Dindo grade IIIA); other complications were managed conservatively (grades I and II). Long-term outcomes were followed up in 98 patients (92%) over a period ranging from 6 months to 8 years. After drainage of solitary and multiple hepatic cysts, no recurrence of clinical symptoms was noted. In five patients (25%) with polycystic liver disease, recurrence of pain syndrome was reported. Conclusion. The accumulated experience with percutaneous sclerotherapy supports its recommendation as a first-line treatment for solitary and multiple non-parasitic hepatic cysts as well as the treatment of choice for polycystic liver disease.